BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pierone G, Henegar C, Fusco J, Vannappagari V, Aboud M, Ragone L, Fusco G. Two-drug antiretroviral regimens: an assessment of virologic response and durability among treatment-experienced persons living with HIV in the OPERA® Observational Database. J Int AIDS Soc 2019;22:e25418. [PMID: 31802641 DOI: 10.1002/jia2.25418] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Teira R, Diaz-cuervo H, Aragão F, Castaño M, Romero A, Roca B, Montero M, Galindo MJ, Muñoz-sánchez MJ, Espinosa N, Peraire J, Martínez E, de la Fuente B, Domingo P, Deig E, Merino MD, Geijo P, Estrada V, Sepúlveda MA, García J, Berenguer J, Currán A. Shorter Time to Discontinuation Due to Treatment Failure in People Living with HIV Switched to Dolutegravir Plus Either Rilpivirine or Lamivudine Compared with Integrase Inhibitor-Based Triple Therapy in a Large Spanish Cohort. Infect Dis Ther. [DOI: 10.1007/s40121-022-00630-y] [Reference Citation Analysis]
2 Gabuzda D, McArthur JC, Letendre SL. Efficacy and safety of two-drug regimens for treatment of HIV in the central nervous system. AIDS 2020;34:1975-7. [PMID: 33009012 DOI: 10.1097/QAD.0000000000002665] [Reference Citation Analysis]
3 Fabbiani M, Rossetti B, Ciccullo A, Oreni L, Lagi F, Celani L, Colafigli M, De Vito A, Mazzitelli M, Dusina A, Durante M, Montagnani F, Rusconi S, Capetti A, Sterrantino G, D'Ettorre G, Di Giambenedetto S; ODOACRE Study Group. Efficacy and durability of two- vs. three-drug integrase inhibitor-based regimens in virologically suppressed HIV-infected patients: Data from real-life ODOACRE cohort. HIV Med 2021. [PMID: 34318591 DOI: 10.1111/hiv.13146] [Reference Citation Analysis]
4 Lee YL, Lin KY, Cheng SH, Lu PL, Wang NC, Ho MW, Yang CJ, Liou BH, Tang HJ, Huang SS, Huang SH, Chen TC, Lin CY, Lin SP, Lee YT, Hung CC; Taiwan HIV Study Group. Dual therapy with dolutegravir plus boosted protease inhibitor as maintenance or salvage therapy in highly experienced people living with HIV. Int J Antimicrob Agents 2021;58:106403. [PMID: 34289404 DOI: 10.1016/j.ijantimicag.2021.106403] [Reference Citation Analysis]
5 Koay WLA, Xiao J, Temprosa M, Happ LP, Monroe AK, Castel AD, Rakhmanina NY; DC Cohort Executive Committee. Short Communication:Outcomes of Dual Versus Triple Antiretroviral Drug Regimens Among Virally Suppressed Adults in the DC Cohort. AIDS Res Hum Retroviruses 2022;38:451-4. [PMID: 35352966 DOI: 10.1089/aid.2021.0202] [Reference Citation Analysis]
6 Koay WLA, Kose-Otieno J, Rakhmanina N. HIV Drug Resistance in Children and Adolescents: Always a Challenge? Curr Epidemiol Rep 2021;:1-11. [PMID: 33758743 DOI: 10.1007/s40471-021-00268-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]